🎯 #Potravitug is a first-in-class monoclonal antibody targeting BK polyomavirus infection in #kidney transplant recipients, a serious complication with no approved treatment.
👉 ysioscapital.com/2026/07/01/i...
#vc
🎯 #Potravitug is a first-in-class monoclonal antibody targeting BK polyomavirus infection in #kidney transplant recipients, a serious complication with no approved treatment.
👉 ysioscapital.com/2026/07/01/i...
#vc
By: Abigail Beaney on Friday, July 25, 2025
By: Abigail Beaney on Friday, July 25, 2025
endpoints.news/ipsen-to-sco...
endpoints.news/ipsen-to-sco...
"PARIS, FRANCE, 22 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. About potravitugPotravitug is a…"
"Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III trial later this year Ipsen expands rare disease portfolio to…"
"Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III trial later this year Ipsen expands rare disease portfolio to…"